Live Breaking News & Updates on Recourse Royalty

Stay updated with breaking news from Recourse royalty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Resubmission of NDA On Track for Early Q2 24— Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24 Company to host conference call today at 8:30amET DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r ....

United States , Judy Matthews , Corey Fishman , Drug Administration , Recourse Royalty , Cash Runway , Chief Executive , Special Protocol Assessment , Resistant Enterobacterales , Complete Response Letter , Financial Advisor , Full Year , Prescription Drug User Fee Act , Exchangeable Senior Subordinated Notes , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Royalty Linked Notes , Maturity Date , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Financial Officer , Consolidated Statement ,

2024-03-28 | NDAQ:ITRM | Press Release | Iterum Therapeutics plc

(2024-03-28 | NDAQ:ITRM) Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results ....

United States , Iterum Closecurlyquote , Corey Fishman , Judy Matthews , Drug Administration , Recourse Royalty , Cash Runway , Chief Executive , Special Protocol Assessment , Resistant Enterobacterales , Complete Response Letter , Financial Advisor , Full Year , Prescription Drug User Fee Act , Linked Notes Closecurlydoublequote , Exchangeable Senior Subordinated Notes , Notes Closecurlydoublequote , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Maturity Date Closecurlydoublequote , Royalty Linked Notes , Maturity Date , Private Securities Litigation Reform Act , Nasdaq Capital Market ,

Iterum Therapeutics Reports Second Quarter 2023 Financial Results

Iterum Therapeutics Reports Second Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Judy Matthews , Corey Fishman , Drug Administration , Japanese Patent Office , Recourse Royalty , Complete Enrollment , Topline Data Expected , Cash Runway , Chief Executive , Trial Ongoing , Resistant Enterobacterales , Japanese Patent Issued , Japanese Patent Registration , Beta Lactam Compounds , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Senior Subordinated Notes , Exchangeable Notes , Maturity Date , Royalty Linked Notes , Private Securities Litigation Reform Act , Nasdaq Capital Market , Quarterly Report , Financial Officer ,

Iterum Therapeutics Reports First Quarter 2022 Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , Judy Matthews , Corey Fishman , Exchange Commission , Silicon Valley Bank , Recourse Royalty , Drug Administration , General Alignment , Key Aspects , Proposed Additional Clinical , Cash Runway , Chief Executive , Exchangeable Senior Subordinated Notes , Exchangeable Notes , Royalty Linked Notes , Global Investment Conference , Antimicrobial Drugs , Uncomplicated Urinary Tract Infections , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Maturity Date , Nasdaq Stock Market , Quarterly Report , Consolidated Statement , Globe Newswire ,